GlassScriptPhysician profile
Tariq Khalil
NPI 1750337457
$2,069.92
in general payments reported to CMS, 2019-2025
27 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $162 · 2021: $304 · 2022: $257 · 2023: $183 · 2024: $523 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $294.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $211.26 | 2019-2025 | Eterna, Proclaim, Freestyle Libre 3 |
| Lilly USA, LLC | $172.34 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $169.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $131.98 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $119.23 | 2021-2025 | |
| Insulet Corporation | $118.65 | 2021-2025 | Omnipod |
| Novo Nordisk INC | $114.73 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.77 | 2023-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $81.26 | 2021-2023 | Gvoke Hypopen |
| Dexcom, INC. | $65.22 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $57.29 | 2020-2025 | Otezla, Repatha |
| Abbvie INC. | $54.10 | 2021-2022 | |
| Philips North America LLC | $52.09 | 2020 | |
| Exact Sciences Corporation | $50.68 | 2024-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.75 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $39.35 | 2021-2022 | |
| Angiodynamics, INC. | $33.35 | 2025 | Auryon Laser System 100-120 Vac |
| Mylan Specialty L.P. | $32.99 | 2022-2023 | Yupelri |
| Saluda Medical Americas, INC. | $27.32 | 2024 | Evoke |
| Astellas Pharma US INC | $24.26 | 2021 | |
| Sumitomo Pharma America, INC. | $18.69 | 2024 | Gemtesa |
| Inspire Medical Systems, INC. | $18.48 | 2025 | Inspire |
| Bardy Diagnostics, INC. | $17.28 | 2022 | |
| Impulse Dynamics (USA) INC. | $17.24 | 2022 | |
| Merck Sharp & Dohme LLC | $14.70 | 2019 | |
| Cequr Corporation | $5.58 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.